Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05892718 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
A Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma, sponsored by FBD Biologics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 8
- Study locations
NCT05892718 is a Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma that is actively recruiting participants, run by FBD Biologics Limited. The registered enrollment target is 80 participants, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT05892718, a Phase 1 study of Advanced Solid Tumor and Refractory Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by FBD Biologics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
Conditions Studied
Interventions
- DRUG HCB101
Study Locations (8)
Other
- Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare - New Taipei City
- National Taiwan University Hospital - Taipei
- Taipei Veterans General Hospital - Taipei
Florida
- Hematology-Oncology Associates of the Treasure Coast - Port Saint Lucie
North Carolina
- Carolina BioOncology - Huntersville
South Carolina
- Greenville Hospital System University Medical Center (ITOR) - Greenville
Texas
- UT Southwestern Medical Center - Dallas
Zhejiang
- Hangzhou First People's Hospital - Hangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2029-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05892718
The ClinicalTrials.gov registry entry for NCT05892718 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (59% lower). The listed sponsor is FBD Biologics Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which HCB101 is the first listed.
NCT05892718 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Other, Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05892718 about?
NCT05892718 is a clinical study titled "A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors". The purpose of this study is to find out whether IV injection of HCB101 is an effective treatment for different types of advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
What is the current status of trial NCT05892718?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2023-10-02. Estimated completion is 2029-11-15.
What conditions does trial NCT05892718 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05892718?
The interventions under investigation include: HCB101 (DRUG).
Who is sponsoring clinical trial NCT05892718?
This trial is sponsored by FBD Biologics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05892718 being conducted?
This trial has 8 study locations across Florida, North Carolina, South Carolina, Texas, Zhejiang. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.